Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) EBITDA: 2023-2024

Historic EBITDA for Artiva Biotherapeutics (ARTV) over the last 2 years, with Dec 2024 value amounting to -$65.8 million.

  • Artiva Biotherapeutics' EBITDA fell 38.47% to -$16.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$65.8 million, marking a year-over-year change of. This contributed to the annual value of -$65.8 million for FY2024, which is 131.63% down from last year.
  • Latest data reveals that Artiva Biotherapeutics reported EBITDA of -$65.8 million as of FY2024, which was down 131.63% from -$28.4 million recorded in FY2023.
  • Artiva Biotherapeutics' 5-year EBITDA high stood at -$28.4 million for FY2023, and its period low was -$65.8 million during FY2024.
  • In the last 2 years, Artiva Biotherapeutics' EBITDA had a median value of -$47.1 million in 2023 and averaged -$47.1 million.
  • Data for Artiva Biotherapeutics' EBITDA shows a maximum YoY crashed of 131.63% (in 2024) over the last 5 years.
  • Artiva Biotherapeutics' EBITDA (Yearly) stood at -$28.4 million in 2023, then plummeted by 131.63% to -$65.8 million in 2024.